JP2023534847A5 - - Google Patents
Info
- Publication number
- JP2023534847A5 JP2023534847A5 JP2023504420A JP2023504420A JP2023534847A5 JP 2023534847 A5 JP2023534847 A5 JP 2023534847A5 JP 2023504420 A JP2023504420 A JP 2023504420A JP 2023504420 A JP2023504420 A JP 2023504420A JP 2023534847 A5 JP2023534847 A5 JP 2023534847A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fusion protein
- cdrs
- cytokine
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054208P | 2020-07-20 | 2020-07-20 | |
| US63/054,208 | 2020-07-20 | ||
| PCT/US2020/062907 WO2022019945A1 (en) | 2020-07-20 | 2020-12-02 | Dual cytokine fusion proteins comprising il-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534847A JP2023534847A (ja) | 2023-08-14 |
| JP2023534847A5 true JP2023534847A5 (enExample) | 2023-12-11 |
Family
ID=79291996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504420A Pending JP2023534847A (ja) | 2020-07-20 | 2020-12-02 | Ｉｌ－１０を含む二重サイトカイン融合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (19) | US11292822B2 (enExample) |
| EP (1) | EP4181957A4 (enExample) |
| JP (1) | JP2023534847A (enExample) |
| KR (1) | KR20230096959A (enExample) |
| CN (1) | CN116322785A (enExample) |
| AU (1) | AU2020459746A1 (enExample) |
| BR (1) | BR112023001187A2 (enExample) |
| CA (1) | CA3186753A1 (enExample) |
| IL (1) | IL300062A (enExample) |
| MX (1) | MX2023000948A (enExample) |
| WO (1) | WO2022019945A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020212598A1 (en) | 2019-04-19 | 2020-10-22 | Synerkine Pharma B.V. | A fusion protein comprising il13 |
| CA3186753A1 (en) * | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| US20230210953A1 (en) * | 2021-12-16 | 2023-07-06 | Deka Biosciences, Inc. | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer |
| CA3244604A1 (en) * | 2022-02-22 | 2023-08-31 | Deka Biosciences, Inc. | METHOD FOR REDUCING A BISPECIFIC T LYMPHOCYTE RECRUITER OR A CHIMERICAL ANTIGEN RECEPTOR T LYMPHOCYTE CYTOKINE RELEASE SYNDROME USING INTERLEUKIN 4 OR 10, OR AN ASSOCIATED FUSION PROTEIN |
| WO2025110822A1 (ko) * | 2023-11-24 | 2025-05-30 | 주식회사 메드팩토 | 피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도 |
| WO2025148750A1 (zh) * | 2024-01-08 | 2025-07-17 | 上药生物治疗（香港）有限公司 | 膜表达il-10及其用途 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞，其制备方法及抗纤维化的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| US8809504B2 (en) * | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| CA2648484A1 (en) | 2006-05-08 | 2007-11-15 | Philogen Spa | Antibody-targeted cytokines for therapy |
| EP2091568A2 (en) | 2006-10-31 | 2009-08-26 | East Carolina University | Fusion proteins comprising a anti-inflammatory cytokine and an antigen for treatment of immune disorders |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| DK3281952T3 (da) | 2007-10-30 | 2020-08-03 | Philogen Spa | Antigen, der er forbundet med reumatoid artritis |
| NO2344540T3 (enExample) | 2008-10-02 | 2018-04-28 | ||
| CA2800488A1 (en) * | 2010-05-26 | 2011-12-01 | Regents Of The University Of Minnesota | Single-chain variable fragment anti-cd133 antibodies and uses thereof |
| WO2012045334A1 (en) | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| ES2872964T3 (es) | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| JP6333730B2 (ja) | 2011-12-12 | 2018-05-30 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| EP2820033A1 (en) | 2012-02-29 | 2015-01-07 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates and their uses |
| PE20150645A1 (es) | 2012-08-08 | 2015-05-11 | Roche Glycart Ag | Proteinas de fusion de interleuquina 10 y usos de las mismas |
| ES2743423T3 (es) * | 2012-10-03 | 2020-02-19 | Philogen Spa | Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal |
| PE20151893A1 (es) | 2013-03-14 | 2015-12-30 | Parkash Gill | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular |
| CA2910044A1 (en) | 2013-04-26 | 2014-10-30 | Philogen S.P.A. | Il4 conjugated to antibodies against extracellular matrix components |
| WO2015117930A1 (en) | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| WO2015175957A1 (en) | 2014-05-16 | 2015-11-19 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| US20160361415A1 (en) | 2015-05-28 | 2016-12-15 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| KR101811050B1 (ko) | 2015-09-02 | 2017-12-21 | 경북대학교 산학협력단 | 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물 |
| WO2017091611A1 (en) | 2015-11-23 | 2017-06-01 | Immungene, Inc | Enhanced cancer immunotherapy using antibody-interferon fusion molecules |
| RU2018124307A (ru) | 2015-12-04 | 2020-01-14 | Новартис Аг | Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции |
| CN106349393B (zh) * | 2015-12-21 | 2020-10-30 | 合肥立方制药股份有限公司 | 一种增强抗体药物稳定性的结构 |
| US20190125840A1 (en) | 2016-04-12 | 2019-05-02 | Philogen S.P.A. | Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US20200306375A1 (en) | 2017-02-22 | 2020-10-01 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| US11939385B2 (en) * | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
| WO2019201866A1 (en) * | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Fusion protein |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| CN121652287A (zh) * | 2019-03-06 | 2026-03-13 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
| EP4087947A4 (en) * | 2020-01-09 | 2024-05-01 | Deka Biosciences, Inc. | METHODS OF USING GENETIC MARKERS, SNPS AND/OR INDELS TO DETERMINE SENSITIVITY TO IL-10 TREATMENT |
| CN115867275A (zh) | 2020-04-13 | 2023-03-28 | 大学健康网络 | 治疗细胞因子释放综合征的方法 |
| CA3186753A1 (en) | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| CA3215528A1 (en) | 2021-05-11 | 2022-11-17 | Salvatore Albani | Chimeric antigen receptors and modified cells comprising the same |
| WO2023114775A2 (en) | 2021-12-13 | 2023-06-22 | Deka Biosciences, Inc. | Dual cytokine fusion proteins comprising multi-subunit cytokines |
| US20230210953A1 (en) | 2021-12-16 | 2023-07-06 | Deka Biosciences, Inc. | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer |
| CA3244604A1 (en) | 2022-02-22 | 2023-08-31 | Deka Biosciences, Inc. | METHOD FOR REDUCING A BISPECIFIC T LYMPHOCYTE RECRUITER OR A CHIMERICAL ANTIGEN RECEPTOR T LYMPHOCYTE CYTOKINE RELEASE SYNDROME USING INTERLEUKIN 4 OR 10, OR AN ASSOCIATED FUSION PROTEIN |
-
2020
- 2020-12-02 CA CA3186753A patent/CA3186753A1/en active Pending
- 2020-12-02 IL IL300062A patent/IL300062A/en unknown
- 2020-12-02 CN CN202080105253.9A patent/CN116322785A/zh active Pending
- 2020-12-02 EP EP20946024.5A patent/EP4181957A4/en active Pending
- 2020-12-02 MX MX2023000948A patent/MX2023000948A/es unknown
- 2020-12-02 WO PCT/US2020/062907 patent/WO2022019945A1/en not_active Ceased
- 2020-12-02 JP JP2023504420A patent/JP2023534847A/ja active Pending
- 2020-12-02 BR BR112023001187A patent/BR112023001187A2/pt unknown
- 2020-12-02 KR KR1020237005848A patent/KR20230096959A/ko active Pending
- 2020-12-02 AU AU2020459746A patent/AU2020459746A1/en active Pending
-
2021
- 2021-03-11 US US17/199,239 patent/US11292822B2/en active Active
-
2022
- 2022-03-01 US US17/684,290 patent/US12263358B2/en active Active
- 2022-03-01 US US17/684,229 patent/US12268903B2/en active Active
- 2022-03-01 US US17/684,243 patent/US11629178B2/en active Active
- 2022-03-01 US US17/684,106 patent/US11572397B2/en active Active
- 2022-03-01 US US17/684,205 patent/US11608368B2/en active Active
- 2022-03-01 US US17/684,272 patent/US11618775B2/en active Active
- 2022-03-01 US US17/684,151 patent/US11613563B2/en active Active
-
2023
- 2023-11-03 US US18/501,914 patent/US12116393B2/en active Active
- 2023-11-03 US US18/501,741 patent/US12121755B2/en active Active
- 2023-11-03 US US18/501,584 patent/US12122814B2/en active Active
- 2023-11-03 US US18/501,884 patent/US12116392B2/en active Active
- 2023-11-03 US US18/501,571 patent/US12145007B2/en active Active
- 2023-11-03 US US18/501,561 patent/US12116389B2/en active Active
- 2023-11-03 US US18/501,856 patent/US12116391B2/en active Active
- 2023-11-03 US US18/501,762 patent/US12006346B2/en active Active
- 2023-11-03 US US18/501,850 patent/US12116390B2/en active Active
- 2023-11-03 US US18/501,581 patent/US12110317B2/en active Active
-
2024
- 2024-10-08 US US18/909,739 patent/US20250135241A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023534847A5 (enExample) | ||
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| JP2024546938A5 (enExample) | ||
| JP2022524018A5 (enExample) | ||
| Strohl et al. | Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells | |
| US20210061925A1 (en) | Trispecific and/or trivalent binding proteins | |
| Dimitrov et al. | Therapeutic antibodies: current state and future trends–is a paradigm change coming soon? | |
| Nelson | Antibody fragments: hope and hype | |
| JP2023513003A5 (enExample) | ||
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| JP2021516975A5 (enExample) | ||
| JP2021516974A5 (enExample) | ||
| JP2022512649A5 (enExample) | ||
| JP2021516976A5 (enExample) | ||
| JP2021515566A5 (enExample) | ||
| IL313525A (en) | Dual cytokine fusion proteins containing multisubunit cytokines | |
| JP7164528B2 (ja) | Ｐｄ－１に特異的に結合する可能な抗体及びその機能的断片 | |
| Teillaud | From whole monoclonal antibodies to single domain antibodies: think small | |
| Roselli et al. | CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al. | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2022551836A (ja) | Ｂｃｍａを標的とする抗体、二重特異性抗体及びその用途 | |
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| Sadeghalvad et al. | Introduction on monoclonal antibodies | |
| JP2024546999A5 (enExample) | ||
| JP2025508882A5 (enExample) |